BACKGROUND: Optimal timing of elective aortic valve replacement (AVR) for severe aortic stenosis (AS) is challenging. Hence, a sensitive marker in AS patients indicating increasing risk after AVR would be of great clinical value. In the present study, we hypothesized that mild-to-moderate pulmonary hypertension (PH) assessed prior to AVR is a sensitive marker for adverse events in patients after successful AVR. METHODS: We enrolled 200 consecutive patients with severe AS undergoing AVR. Among them, 176 patients (88%) were symptomatic. Patients were divided according to systolic pulmonary artery pressure (PAP(sys)) into three groups: no PH (PAP(sys) <30 mmHg), mild-to-moderate PH (PAP(sys) ≥30 and PAP(sys) <60 mmHg) and severe PH (≥60 mmHg). Multivariable analyses were adjusted for age and gender and included PH, left ventricular ejection fraction ≤35%, renal insufficiency and logistic EuroSCORE ≥20%. Primary endpoint was death of any cause within 5 years after AVR. RESULTS: During follow-up, 23 patients died (cumulative 5-year mortality rate 14.6%). Patients without (n = 78), mild-to-moderate (n = 99) and severe PH (n = 23) had 5-year mortality rates of 2.6, 15.2 and 26.1% (p = 0.001). PAPsys ≥30 mmHg yielded an excellent level of sensitivity of 92.8%. On multivariable analysis, mild-to-moderate PH was the only independent risk factor (hazard ratio 4.9, 95% confidence interval 1.1-21.8). CONCLUSIONS: In patients with severe AS undergoing AVR, mild-to-moderate PH is a strong and independent predictor of late mortality. Conversely, patients with normal PAP(sys) have an extremely good prognosis.
BACKGROUND: Optimal timing of elective aortic valve replacement (AVR) for severe aortic stenosis (AS) is challenging. Hence, a sensitive marker in AS patients indicating increasing risk after AVR would be of great clinical value. In the present study, we hypothesized that mild-to-moderate pulmonary hypertension (PH) assessed prior to AVR is a sensitive marker for adverse events in patients after successful AVR. METHODS: We enrolled 200 consecutive patients with severe AS undergoing AVR. Among them, 176 patients (88%) were symptomatic. Patients were divided according to systolic pulmonary artery pressure (PAP(sys)) into three groups: no PH (PAP(sys) <30 mmHg), mild-to-moderate PH (PAP(sys) ≥30 and PAP(sys) <60 mmHg) and severe PH (≥60 mmHg). Multivariable analyses were adjusted for age and gender and included PH, left ventricular ejection fraction ≤35%, renal insufficiency and logistic EuroSCORE ≥20%. Primary endpoint was death of any cause within 5 years after AVR. RESULTS: During follow-up, 23 patients died (cumulative 5-year mortality rate 14.6%). Patients without (n = 78), mild-to-moderate (n = 99) and severe PH (n = 23) had 5-year mortality rates of 2.6, 15.2 and 26.1% (p = 0.001). PAPsys ≥30 mmHg yielded an excellent level of sensitivity of 92.8%. On multivariable analysis, mild-to-moderate PH was the only independent risk factor (hazard ratio 4.9, 95% confidence interval 1.1-21.8). CONCLUSIONS: In patients with severe AS undergoing AVR, mild-to-moderate PH is a strong and independent predictor of late mortality. Conversely, patients with normal PAP(sys) have an extremely good prognosis.
Authors: F Roques; S A Nashef; P Michel; E Gauducheau; C de Vincentiis; E Baudet; J Cortina; M David; A Faichney; F Gabrielle; E Gams; A Harjula; M T Jones; P P Pintor; R Salamon; L Thulin Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: Juan F Delgado; Esther Conde; Violeta Sánchez; Fernando López-Ríos; Miguel A Gómez-Sánchez; Pilar Escribano; Teresa Sotelo; Agustín Gómez de la Cámara; José Cortina; Carlos S de la Calzada Journal: Eur J Heart Fail Date: 2005-10 Impact factor: 15.534
Authors: Manuel Carnero-Alcázar; Fernando Reguillo-Lacruz; Ali Alswies; Enrique Villagrán-Medinilla; Luis Carlos Maroto-Castellanos; Joséenrique Rodríguez-Hernández Journal: Interact Cardiovasc Thorac Surg Date: 2010-01-25
Authors: Dimitry Schewel; Jury Schewel; Julia Martin; Lisa Voigtländer; Christian Frerker; Peter Wohlmuth; Thomas Thielsen; Karl-Heinz Kuck; Ulrich Schäfer Journal: Clin Res Cardiol Date: 2014-11-04 Impact factor: 5.460
Authors: Alexander Sedaghat; Jan-Malte Sinning; Mariuca Vasa-Nicotera; Alexander Ghanem; Christoph Hammerstingl; Eberhard Grube; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2013-07-23 Impact factor: 5.460
Authors: Christine S Zuern; Christian Eick; Konstantinos D Rizas; Cosmina Stoleriu; Petra Barthel; Christian Scherer; Karin A L Müller; Meinrad Gawaz; Axel Bauer Journal: Clin Res Cardiol Date: 2012-02-24 Impact factor: 5.460
Authors: Zisis Dimitriadis; Marcus Wiemer; Werner Scholtz; Lothar Faber; Cornelia Piper; Thomas Bitter; Ippokratis Messaritakis; Kevin Bullert; Jochen Boergermann; Georg Kleikamp; Christian Prinz; Dieter Horstkotte; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2013-08-21 Impact factor: 5.460